Abstract
Weak or absent peristalsis of the esophageal musculature is a common finding in ambulatory patients suffering from dysphagia and frequently associated with gastroesophageal reflux. There is currently no pharmacologic intervention that reliably improves esophageal contractility in patients suffering from various esophageal motility disorders. Our objective was to evaluate the acute effects of pyridostigmine on high-resolution manometry parameters in patients suffering from dysphagia with evidence of esophageal dysmotility. Pyridostigmine is an acetylcholinesterase inhibitor which increases effective concentrations of acetylcholine at the neuromuscular junction of both striated and smooth muscle cells. We conducted a prospective crossover study of five patients with dysphagia and proven esophageal dysmotility. Three patients had baseline ineffective esophageal motility and two had achalasia. Patients underwent pharyngeal and esophageal manometry before and after pyridostigmine administration. The median distal contractile integral (DCI), a marker of esophageal contractile vigor, was significantly higher post pyridostigmine administration 3001 (1950.3–3703.2) mmHg × s × cm compared to pre-pyridostigmine DCI of 1229.9 (956.2–2100) mmHg × s × cm; P < 0.001. Pre-pyridostigmine 18/25 (72%) of the patient’s swallows was peristaltic compared to 25/25 (100%) post-pyridostigmine; P < 0.005. No other pharyngeal or esophageal high-resolution manometry parameter differed significantly after pyridostigmine administration. The results of this pilot study demonstrate that pyridostigmine acutely improves esophageal contractile vigor in patients suffering from dysphagia with esophageal dysmotility. Further investigation with larger sample size, longer follow-up, side effect profile, and patient-reported outcome measures is still needed to determine the clinical usefulness of pyridostigmine in specific disorders of esophageal motility.
Similar content being viewed by others
References
Ashraf HH, Palmer J, Dalton HR, Waters C, Luff T, Strugnell M, et al. Can patients determine the level of their dysphagia? World J Gastroenterol. 2017;23:1038–43.
Roeder BE, Murray JA, Dierkhising RA. Patient localization of esophageal dysphagia. Dig Dis Sci. 2004;49:697–701.
Nouraei S a. R, Murray IA, Heathcote KJ, Dalton HR. Oesophageal causes of dysphagia localised only to the pharynx: Implications for the suspected head and neck cancer pathway. Clin Otolaryngol. 2018;
Gyawali CP, Sifrim D, Carlson DA, Hawn M, Katzka DA, Pandolfino JE, et al. Ineffective esophageal motility: concepts, future directions, and conclusions from the Stanford 2018 symposium. Neurogastroenterol Motil. 2019;31:e13584.
Jain A, Baker JR, Chen JW. In ineffective esophageal motility, failed swallows are more functionally relevant than weak swallows. Neurogastroenterol Motil. 2018;30:e13297.
Hollenstein M, Thwaites P, Bütikofer S, Heinrich H, Sauter M, Ulmer I, et al. Pharyngeal swallowing and oesophageal motility during a solid meal test: a prospective study in healthy volunteers and patients with major motility disorders. Lancet Gastroenterol Hepatol. 2017;2:644–53.
Ho S-C, Chang C-S, Wu C-Y, Chen G-H. Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease. Dig Dis Sci. 2002;47:652–6.
Aggarwal N, Thota PN, Lopez R, Gabbard S. A randomized double-blind placebo-controlled crossover-style trial of buspirone in functional dysphagia and ineffective esophageal motility. Neurogastroenterol Motil. 2018. https://doi.org/10.1111/nmo.13213.
Mashimo H, Goyal RK. Physiology of esophageal motility. GI motility online [internet]. Berlin: Nature Publishing Group; 2006.
Blonski W, Vela MF, Freeman J, Sharma N, Castell DO. The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. J Clin Gastroenterol. 2009;43:253–60.
Belafsky PC, Kuhn M. The clinician’s guide to swallowing fluoroscopy [internet]. New York: Springer; 2014.
Kahrilas PJ, et al. The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27:160–74.
Arffa RE, Krishna P, Gartner-Schmidt J, Rosen CA. Normative values for the voice handicap index-10. J Voice. 2012;26:462–5.
Belafsky PC, Mouadeb DA, Rees CJ, Pryor JC, Postma GN, Allen J, et al. Validity and reliability of the eating assessment tool (EAT-10). Ann Otol Rhinol Laryngol. 2008;117:919–24.
Crary MA, Mann GDC, Groher ME. Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. Arch Phys Med Rehabil. 2005;86:1516–20.
Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice. 2002;16:274–7.
Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig. 2011;31:691–701.
Omari TI, Ciucci M, Gozdzikowska K, Hernández E, Hutcheson K, Jones C, et al. High-resolution pharyngeal manometry and impedance: protocols and metrics-recommendations of a high-resolution pharyngeal manometry international working group. Dysphagia. 2020;35:281–95.
Leonard R, Rees CJ, Belafsky P, Allen J. Fluoroscopic surrogate for pharyngeal strength: the pharyngeal constriction ratio (PCR). Dysphagia. 2011;26:13–7.
Roman S, Kahrilas PJ, Mion F, Nealis TB, Soper NJ, Poncet G, et al. Partial recovery of peristalsis after myotomy for achalasia; more the rule than the exception. JAMA Surg. 2013;148:157–64.
Goyal RK, Chaudhury A. Physiology of normal esophageal motility. J Clin Gastroenterol. 2008;42:610–9.
O’Rourke A, Weinberger P, Morrison M, Conklin J, Postma G. Topical bethanechol for the improvement of esophageal dysmotility: a pilot study: annals of otology, rhinology & laryngology [internet]. Los Angeles, CA: SAGE; 2013.
Drachman DB. Myasthenia gravis. Semin Neurol. 2016;36:419–24.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Authors declare that they have no conflict of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Dhar, S.I., Nativ-Zeltzer, N., Mehdizadeh, O.B. et al. Effects of Pyridostigmine on Esophageal and Pharyngeal Motility in Dysphagic Patients Undergoing High-Resolution Manometry. Dysphagia 37, 4–10 (2022). https://doi.org/10.1007/s00455-020-10243-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00455-020-10243-7